Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Daniel Orbach; Max Van Noesel; Bernadette Brennan; Nadège Corradini; Rita Alaggio; Myriam Ben Arush; Reineke A Schoot; Pablo Berlanga; Ilaria Zanetti; Lisa Lyngsie Hjalgrim; Federica Di Corti; Gema Ramirez; Michela Casanova; Andrea Ferrari

doi:10.1002/pbc.29882

Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Daniel Orbach, Max Van Noesel, Bernadette Brennan, Nadège Corradini, Rita Alaggio, Myriam Ben Arush, Reineke A Schoot, Pablo Berlanga, Ilaria Zanetti, Lisa Lyngsie Hjalgrim, Federica Di Corti, Gema Ramirez, Michela Casanova, Andrea Ferrari

Group van Noesel

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

1 Citaat (Scopus)

Samenvatting

The European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS-05 (EUDRACT 2005-001139-31) and in MTS-2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0-18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow-up of 50 months (range, 6-176) for living patients, nine patients remain alive off therapy and two died. Five-year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5-93.9) and 74.1% (95% CI: 28.1-93.0).

Originele taal-2	Engels
Pagina's (van-tot)	e29882
Tijdschrift	Pediatric blood & cancer
Volume	69
Nummer van het tijdschrift	10
Vroegere onlinedatum	16 jul. 2022
DOI's	https://doi.org/10.1002/pbc.29882
Status	Gepubliceerd - okt. 2022

Trefwoorden

children
hemangioendothelioma
soft tissue sarcoma
surgery

Toegang tot document

10.1002/pbc.29882

Citeer dit

Orbach, D., Van Noesel, M., Brennan, B., Corradini, N., Alaggio, R., Ben Arush, M., Schoot, R. A., Berlanga, P., Zanetti, I., Hjalgrim, L. L., Di Corti, F., Ramirez, G., Casanova, M., & Ferrari, A. (2022). Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience. Pediatric blood & cancer, 69(10), e29882. https://doi.org/10.1002/pbc.29882

@article{137f1e1b567846c0819764e854719914,

title = "Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience",

abstract = "The European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS-05 (EUDRACT 2005-001139-31) and in MTS-2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0-18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow-up of 50 months (range, 6-176) for living patients, nine patients remain alive off therapy and two died. Five-year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5-93.9) and 74.1% (95% CI: 28.1-93.0).",

keywords = "Clinical Studies as Topic, Sarcoma/pathology, Humans, Adolescent, Soft Tissue Neoplasms/pathology, Hemangioendothelioma, Epithelioid/therapy, Child, children, hemangioendothelioma, soft tissue sarcoma, surgery",

author = "Daniel Orbach and {Van Noesel}, Max and Bernadette Brennan and Nad{\`e}ge Corradini and Rita Alaggio and {Ben Arush}, Myriam and Schoot, {Reineke A} and Pablo Berlanga and Ilaria Zanetti and Hjalgrim, {Lisa Lyngsie} and {Di Corti}, Federica and Gema Ramirez and Michela Casanova and Andrea Ferrari",

note = "{\textcopyright} 2022 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.",

year = "2022",

month = oct,

doi = "10.1002/pbc.29882",

language = "English",

volume = "69",

pages = "e29882",

journal = "Pediatric blood & cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "10",

}

Orbach, D, Van Noesel, M, Brennan, B, Corradini, N, Alaggio, R, Ben Arush, M, Schoot, RA, Berlanga, P, Zanetti, I, Hjalgrim, LL, Di Corti, F, Ramirez, G, Casanova, M & Ferrari, A 2022, 'Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience', Pediatric blood & cancer, vol. 69, nr. 10, blz. e29882. https://doi.org/10.1002/pbc.29882

TY - JOUR

T1 - Epithelioid hemangioendothelioma in children

T2 - The European Pediatric Soft Tissue Sarcoma Study Group experience

AU - Orbach, Daniel

AU - Van Noesel, Max

AU - Brennan, Bernadette

AU - Corradini, Nadège

AU - Alaggio, Rita

AU - Ben Arush, Myriam

AU - Schoot, Reineke A

AU - Berlanga, Pablo

AU - Zanetti, Ilaria

AU - Hjalgrim, Lisa Lyngsie

AU - Di Corti, Federica

AU - Ramirez, Gema

AU - Casanova, Michela

AU - Ferrari, Andrea

PY - 2022/10

Y1 - 2022/10

N2 - The European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS-05 (EUDRACT 2005-001139-31) and in MTS-2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0-18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow-up of 50 months (range, 6-176) for living patients, nine patients remain alive off therapy and two died. Five-year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5-93.9) and 74.1% (95% CI: 28.1-93.0).

AB - The European pediatric Soft tissue sarcoma Study Group analyzed all children with epithelioid hemangioendothelioma prospectively registered in the NRSTS-05 (EUDRACT 2005-001139-31) and in MTS-2008 (NCT00379457) studies: 10 patients with localized and one with metastatic disease. Median age was 14.3 years (range, 9.0-18.8). Local therapy was initial primary surgery in seven cases, and five patients received systemic therapy. No patients received radiotherapy. After a median follow-up of 50 months (range, 6-176) for living patients, nine patients remain alive off therapy and two died. Five-year progression free and overall survivals are, respectively, 77.1% (95% confidence interval [CI]: 34.5-93.9) and 74.1% (95% CI: 28.1-93.0).

KW - Clinical Studies as Topic

KW - Sarcoma/pathology

KW - Humans

KW - Adolescent

KW - Soft Tissue Neoplasms/pathology

KW - Hemangioendothelioma, Epithelioid/therapy

KW - Child

KW - children

KW - hemangioendothelioma

KW - soft tissue sarcoma

KW - surgery

UR - https://www.mendeley.com/catalogue/d8bc9ddb-fa38-39f2-9471-6ba071ed1471/

U2 - 10.1002/pbc.29882

DO - 10.1002/pbc.29882

M3 - Article

C2 - 35841307

SN - 1545-5009

VL - 69

SP - e29882

JO - Pediatric blood & cancer

JF - Pediatric blood & cancer

IS - 10

ER -

Epithelioid hemangioendothelioma in children: The European Pediatric Soft Tissue Sarcoma Study Group experience

Samenvatting

Trefwoorden

Toegang tot document

Vingerafdruk

Citeer dit